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Abstract
Background: Engagement of CD40 promotes survival of undifferentiated nasopharyngeal carcinoma (UNPC)
cells and similar effects are induced by the EBV oncoprotein LMP-1 that is expressed in a fraction of cases.
Considering that CD40 may be activated also by the soluble isoform of CD40L (sCD40L), we investigated the
serum levels of sCD40L in a series of 61 UNPC patients from Italy, a non-endemic area for this disease.
Results: At diagnosis, serum samples of UNPC patients contained significantly higher levels of sCD40L than age-
matched healthy controls (p < 0.001). High levels of sCD40L (i.e., >18 ng/ml) were more frequently found in
patients <40 years of age (p = 0.03) and with distant metastases at presentation (p = 0.03). Serum levels of
sCD40L were inversely associated with the expression of the EBV oncoprotein LMP-1 (p = 0.03), which mimics
a constitutively activated CD40. The amount of sCD40L decreased in a fraction of patients treated with local
radiotherapy alone. Moreover, CD40L+ lymphoid cells admixed to neoplastic UNPC cells were detected in cases
with high serum levels of sCD40L, suggesting that sCD40L is probably produced within the tumor mass.
Conclusion: sCD40L may contribute to CD40 activation in UNPC cells, particularly of LMP-1-negative cases,
further supporting the crucial role of CD40 signalling in the pathogenesis of UNPC. sCD40L levels may be useful
to identify UNPC patients with occult distant metastases at presentation.
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Background
Undifferentiated nasopharyngeal carcinoma (UNPC)
constitutes the most common epithelial malignancy
occurring in the nasopharynx, and is characterized by
peculiar epidemiologic and clinicopathologic features
[1,2]. UNPC has a high incidence in Southern China and
Southeast Asia, whereas it is a rare disease in Europe and
North America. Moreover, compared to other head and
neck carcinomas, UNPC shows higher invasive and meta-
static potential, being frequently diagnosed only after dis-
semination [3-5]. The presence of a highly cellular
lymphoid stroma, admixed with neoplastic cells, repre-
sents a peculiar morphologic feature of UNPC. The major-
ity of infiltrating cells is constituted by non-neoplastic T
lymphocytes, but other reactive elements such as macro-
phages, plasma cells, eosinophils, and neutrophils, are
also present in varying proportions [6,7]. Although the
role of lymphoid stroma in UNPC is still poorly defined,
immunophenotypic analyses have demonstrated that
infiltrating T lymphocytes and tumor cells express several
immune regulatory receptor/ligand pairs [8,9], suggesting
that biologically relevant interactions between the two
cell components probably occur in vivo.
Multiple factors contribute to the pathogenesis of UNPC,
including genetic predisposition, environmental factors,
and Epstein-Barr virus (EBV) infection [1,2,10,11]. In par-
ticular, EBV genomes are detected in virtually all UNPC
worldwide and are monoclonal, consistent with a causal
role for the virus [1,2,10]. EBV infection in UNPC cells is
characterized by the expression of a limited set of latent
proteins, including EBNA-1, LMP-1, and LMP-2 [1,2,10].
The LMP-1 protein transforms B both lymphocytes and
rodent fibroblasts ad may contribute to the invasive and
metastatic potential of carcinoma cells [12,13]. Recent
evidence indicates that LMP-1 functions as a constitutively
active tumor necrosis factor (TNF) receptor being able to
recruit cellular signal transducing molecules in the C-ter-
minus of the protein, resulting in the activation of several
signaling pathways in a ligand-independent manner [14].
In particular, LMP-1 shares several functional properties
with activated CD40, a member of the TNF receptor super-
family, being able, in certain instances, to substitute for
CD40 in vivo [15,16].
CD40 binds to a ligand (CD40L) which is an ~35 kDa
transmembrane protein expressed on activated T cells,
mast cells, basophilis, eosinophils, and activated platelets
[17,18]. The interaction between CD40 and CD40L is cru-
cial for B-cell activation, antibody production, isotype
switching and cell-mediated immune responses
[17,19,20]. Moreover, the CD40 pathway is also involved
in regulating the growth and survival of normal and trans-
formed epithelial cells [21,22]. In particular, CD40 trig-
gering on UNPC cells may directly convey survival signals,
being able to prevent Fas-mediated apoptosis [23]. Like
other members of the TNF family, CD40L exists also as a
soluble isoform (sCD40L) produced by enzymatic cleav-
age at a metalloproteinase-sensitive site in the membrane-
proximal region of the extracellular domain of the mole-
cule [24,25]. sCD40L is biologically active and can
replace, at least in vitro, the normal T-cell-derived CD40L
signal to CD40-bearing cells [24,25]. sCD40L can be
detected in the serum of healthy individuals and elevated
levels have been reported in patients with autoimmune
diseases [26-28], hepatitis B virus infection [26], lympho-
proliferative disorders [29], and lung cancer [30]. Never-
theless, no information is currently available on the
presence and amount of sCD40L in the serum of UNPC
patients.
We therefore sought to determine the serum levels of
sCD40L in a series of UNPC patients from Italy, a non-
endemic area for this disease. The study was undertaken
with the aim to identify potential associations between
circulating levels of sCD40L and the virologic and clinico-
pathologic parameters of UNPC at diagnosis, and to
define the predictive and prognostic value of serum
sCD40L.
Results
UNPC patients have higher serum levels of sCD40L than 
healthy donors
The individual and tumor-related characteristics of UNPC
patients investigated are described in Table 1. Mean serum
levels of sCD40L were significantly higher (approximately
3-fold) in UNPC patients than in healthy donors (15.2 ±
6.4 vs. 6.3 ± 3.6 ng/ml; p < 0.001) (Figure 1). Table 2
shows the results of the comparison of the sCD40L levels
with regard to demographic and presenting clinical fea-
tures of UNPC patients. Patients with sCD40L levels of in
the highest category (>18 ng/ml) were more frequently
<40 years old (8/16, 50% vs. 12/45, 26.7%; p = 0.03)
(Table 2). No correlation was found between sCD40L lev-
els and T stage or regional lymph node involvement
(Table 2), whereas a significantly higher proportion of
UNPC patients with distant metastases at presentation
carried high amounts (>18 ng/ml) of sCD40L (6/8, 75%
vs. 13/51, 25.5%; p = 0.03). Forty-one (69.5%) of the 59
UNPC patients investigated showed detectable amounts
of EBV DNA in the serum (median: 16502 copies/ml;
range 128–162.756 copies/ml), whereas 18 (30.5%) were
negative. No association was found between serum
sCD40L levels and EBV DNA load.
Serum levels of sCD40L were inversely associated with 
LMP-1 expression by tumor cells
Expression of LMP-1 was detected by immunohistochem-
istry in the large majority of tumor cells of 9 of 51 cases
(17.6%) (Figure 2). Serum sCD40L levels were inverselyInfectious Agents and Cancer 2007, 2:5 http://www.infectagentscancer.com/content/2/1/5
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associated with LMP-1 expression, as shown by the more
frequent detection of high levels of sCD40L in LMP-1-neg-
ative cases (23/42, 54.8%), as compared to LMP-1-posi-
tive UNPC patients (1/9, 11.1%; p = 0.03) (Table 2).
Serum sCD40L was not associated with the generation of 
active thrombin
sCD40L may be released by platelets activated as a conse-
quence of thrombin generation [18,31]. Therefore, the
pro-thrombin F1+2 fragment was analyzed as a coagula-
tion activation marker because it provides an accurate esti-
mate of the generation of active thrombin. Plasma
samples from UNPC patients (n = 32) showed slightly
higher levels of F1+2 compared with healthy donors (n =
30), although the mean levels detected in both groups
were within the range of normality indicated by the man-
ufacturer (0.91 ± 0.45 vs. 0.62 ± 0.26 nmol/L, not signifi-
cant). Moreover, no correlation was found between the
plasma F1+2 levels and the amount of serum sCD40L in
the UNPC patients investigated for both analyses.
Detection of CD40L expression on circulating T 
lymphocytes from UNPC patients
Membrane CD40L expression was investigated in circulat-
ing T cells from 9 UNPC patients and 16 healthy donors.
Un-stimulated CD3+ T cells in both groups failed to
express CD40L. After in vitro stimulation with PMA and
ionomycin for 5 hours, CD3+CD8- cells from both UNPC
patients and healthy controls displayed increased CD40L
expression, whereas only a negligible number of
CD3+CD8+ cells up-regulated CD40L (usually <2%).
Notably, a significantly lower percentage of CD3+CD8- T
cells from UNPC patients up-regulated CD40L upon stim-
ulation as compared to controls (22.6 ± 9.1 vs. 47.4 ± 7.6;
p < 0.001) (Figure 3). The difference remained statistically
significant also after correction for the number of CD4+
cells (not shown).
Expression of CD40L by tumor infiltrating lymphocytes
Preliminary experiments carried out in frozen tissue sec-
tions from reactive lymph nodes, demonstrated that the
expression of CD154/CD40L was restricted to small lym-
phocytes, confirming previous studies [32,33]. These cells
displayed a prominent dot-like pattern or punctate para-
nuclear staining, whereas a small number of positive cells
exhibited a membrane staining pattern. The same analysis
carried out in UNPC biopsies showed that tumor cells
were CD40L-negative in all cases. Conversely, a variable
number (1–10%) of non-neoplastic lymphoid cells in
areas involved by UNPC were CD40L+. CD40L+ lym-
phocytes were intermingled with tumor cells and/or
located around UNPC tumor nests. In all 5 cases, CD40L
expression was correlated with the serum levels of
sCD40L. The three cases with more than 5% CD40L+
Table 1: Distribution of 61 patients with undifferentiated nasopharyngeal carcinoma (UNPC) according to selected characteristics. 
North-East Italy, 1994–2003.
Characteristics UNPC patients
Age (years)
Range 14–78
Median 49.6
Sex N. (%)
Female 17 (27.9)
Male 44 (72.1)
T stage
T1 13 (21.7)
T2 27 (45.0)
T3 11 (18.3)
T4 9 (15.0)
N stage
N0 13 (22.1)
N1 23 (39.0)
N2 12 (20.3)
N3 11 (18.6)
M stage
M0 51 (86.4)
M1 8 (13.6)
Stage
I-II 20 (32.8)
III-IV 32 (52.5)
Levels of sCD40L
High 20 (32.8)
Medium-low 41 (67.2)Infectious Agents and Cancer 2007, 2:5 http://www.infectagentscancer.com/content/2/1/5
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infiltrating lymphocytes (Figure 4A) had higher levels of
sCD40L. Conversely, two cases with a lower content of
CD40L+ lymphocytes (<5%) (Figure 4B) were those with
lower sCD40L levels.
Treatment response and survival
All but seven patients completed the treatment, CR rate
occurred in 82% of evaluable patients. After a median fol-
low-up of 37.6 months (range 2.5–154), 16% and 11% of
patients developed loco-regional and distant relapse,
respectively. Distribution of treatment modalities and CR
rate were comparable between patients with high (> 18
ng/ml) and medium-low (≤18 ng/ml) levels of serum
sCD40L. Patients with higher sCD40L levels developed
more frequently distant failure, whereas patients with
medium-low levels developed loco-regional failure, but
the difference in the pattern of relapse was of borderline
significance (p = 0.07) (Table 2). Patients treated with RT
alone had a marked decrease in serum sCD40L levels, but
the average difference (3.9 ng/ml) between levels before
and after RT was of borderline statistical significance (p =
0.07). The 5-year DFS and OS rates were 81% and 62%,
respectively. There was no significant association between
the sCD40L levels and outcome (Table 3). Patients with
medium-low sCD40L levels had 5-year DFS and OS rates
of 83% (95% CI: 68.5%–96.4%) and 62% (95% CI:
46.4%–70.2%), respectively, whereas patients with higher
sCD40L levels had a 5-year DFS and OS of 80% (95% CI:
60%–100%) and 59% (95% CI: 35.3%–83.5%).
Discussion
The CD40-CD40L interaction plays a central role in the
regulation of immune responses and mediates diverse
biological responses that may contribute to the growth
and survival of tumor cells. The relevance of CD40-
dependent signaling in tumor development is also
emphasized by the observation that the oncogenic prop-
erties of the EBV protein LMP-1 are due to its ability to
hijack part of the CD40 cascade [14-16]. In the present
study, we demonstrate that UNPC patients have signifi-
cantly increased serum levels of sCD40L compared with
healthy donors of similar sex and age. Interestingly,
UNPC patients 40 years-old or younger carried higher
amounts of serum sCD40L, an observation that further
Table 2: Comparison of patients with undifferentiated nasopharyngeal carcinoma according to sCD40L levels and personal 
characteristics and presenting clinical features. North-East Italy, 1994–2003.
Characteristic§ Levels of sCD40L
High Medium-Low p
No. (%) No. %
Age:
<= 39 8 (40.0) 8 (20.0)
40–54 9 (45.0) 14 (35.0)
>= 55 3 (15.0) 18 (45.0) 0.02
Sex:
Men 16 (80.0) 28 (68.3)
Women 4 (20.0) 13 (31.7) 0.51
T:
1 4 (20.0) 9 (23.1)
2A-2B 8 (40.0) 18 (46.2)
3–4 8 (40.0) 12 (30.8) 0.78
N:
0 2 (10.0) 11 (28.9)
1 10 (50.0) 12 (31.6)
2–3 8 (40.0) 15 (39.5) 0.36
M:
0 13 (68.4) 38 (95.0)
1 6 (31.6) 2 (5.0) 0.01
Stage:
I-II 6 (31.6) 14 (42.4)
III-IVa-IVb 7 (36.8) 17 (51.5)
IVc 6 (31.6) 2 (6.1) 0.11
LMP-1 expression
Negative cases 23 (95.8) 19 (70.4)
Positive cases 1 (4.2) 8 (29.6) 0.03
§In some items, the sum does not add up to the total because of missing valuesInfectious Agents and Cancer 2007, 2:5 http://www.infectagentscancer.com/content/2/1/5
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supports the hypothesis that UNPC of young people has
distinctive epidemiologic and clinico-pathologic features
[1,2]. In fact, while in endemic areas UNPC does not usu-
ally occur before 45 years of age [34], in North Africa this
tumor also affects young people [1,2,7,35-37], represent-
ing 25% of all UNPC-affected patients [38]. Italian UNPC
patients have similar epidemiologic features, as shown by
a previous retrospective study [39] and by the finding that
28% of patients from the present series were 40 years-old
or younger.
Several lines of evidence indicates that tumor cells may
shed pro-coagulant factors that can be responsible for the
generation of active thrombin [40]. This, in turn, may lead
to platelet activation and the consequent release of vari-
ous factors, including sCD40L [3,41]. In UNPC patients,
however, the mean plasma levels of F1+2 were within the
normal range, excluding thus an increased generation of
active thrombin. These findings, together with the lack of
correlation between the F1+2 levels and the amount of
serum sCD40L, rule out that sCD40L is mainly released
from platelets in UNPC patients. Moreover, the lack of
membrane CD40L in circulating T cells also excludes that
a systemic activation of the immune system may be
responsible for enhanced release of sCD40L. Interestingly,
upon activation, the percentage of CD40L+ T helper cells
was significantly reduced in UNPC patients as compared
to controls. Similar findings were also observed in HIV-
infected children [42]. This effect is probably not due to
the loss of distinct subpopulations of T helper lym-
phocytes, since Italian UNPC patients carry percentages
and absolute numbers of CD4+ memory (CD45R0+),
CD4+ naive (CD45RA+/CD62L+) and activated (HLA-
DR+) CD4+ lymphocytes similar to those of healthy
UNPC patients (n = 61) show increased levels of serum sCD40L compared to healthy donors (n = 71) matched for sex and  age Figure 1
UNPC patients (n = 61) show increased levels of serum sCD40L compared to healthy donors (n = 71) matched for sex and 
age. The difference between the two groups was statistically significant (p < 0.001).Infectious Agents and Cancer 2007, 2:5 http://www.infectagentscancer.com/content/2/1/5
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donors [[43], our unpublished results]. Our findings
rather support the hypothesis of an underlying functional
defect of T cell responses in these patients, as also sug-
gested by previous reports [44,45]. In particular, some of
us have recently demonstrated that circulating CD4+ T
lymphocytes from Italian UNPC patients showed
impaired IL-2 secretion and increased IL-10 production,
consistently with a Th1/Th2 dysregulation [43]. Neverthe-
less, the nature and the mechanisms responsible for these
functional abnormalities are not yet established and war-
rants further investigation.
Unlike what observed in circulating T cells, tumor infil-
trating lymphocytes expressed membrane CD40L in all
cases investigated, consistently with previous findings [8].
Besides strengthening the pathogenic relevance of the
interactions occurring between UNPC cells and infiltrat-
ing lymphocytes, these results also suggest that sCD40L
may be released within tumor microenvironment by acti-
vated T cells. This possibility is also supported by the find-
ing that the amount of sCD40L in the serum may decrease
in patients treated with local radiotherapy alone. Intrigu-
ingly, serum levels of sCD40L were inversely correlated
with LMP-1 expression by tumor cells, suggesting that
LMP-1-negative UNPC cells may require CD40 activation
for growth and/or survival. These findings are in line with
the known ability of LMP-1 to usurp part of CD40-
dependent signalling and reinforce the notion that CD40
activation is of pathogenic relevance for UNPC
[8,15,16,23].
Within tumor tissue, CD40 triggering by both CD40L+
lymphocytes and sCD40L may directly activate signalling
pathways contributing to the transformed phenotype of
UNPC cells, particularly in the LMP-1-negative cases. It is
worth considering that CD40 activation may enhance the
Detection of LMP-1 expression by immunohistochemistry (red) in UNPC tumor cells Figure 2
Detection of LMP-1 expression by immunohistochemistry (red) in UNPC tumor cells. Alkaline phosphatase anti-alkaline phos-
phatase, original magnification ×250.Infectious Agents and Cancer 2007, 2:5 http://www.infectagentscancer.com/content/2/1/5
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invasive potential of a variety of cells through the induc-
tion of matrix metalloproteinases [46-49], enzymes that
efficiently degrade extracellular matrix proteins [50,51],
favoring thus the metastatic process. Indeed, in our UNPC
series, serum sCD40L levels were not correlated with T
stage or regional lymph node involvement, ruling out any
relationship with loco-regional tumor burden. Con-
versely, a significantly higher proportion of UNPC
patients with distant metastases at presentation carried
high levels of sCD40L, suggesting a possible contribution
of this factor to an early hematogenous spreading of
UNPC cells. The high levels of sCD40L detected in the
serum of UNPC patients may also prevent apoptosis of
UNPC cells circulating in the blood and favour their sur-
vival and/or growth after localization at distant sites.
Moreover, considering that matrix metalloproteinases are
involved in the generation of sCD40L [24,24], local pro-
duction of these enzymes induced by CD40 triggering
may in turn enhance the release of sCD40L.
While sCD40L levels may be useful to identify UNPC
patients with occult distant metastasis at presentation, our
study indicate that the amount of serum sCD40L does not
provide a reliable estimate of tumor burden. This is in
Membrane CD40L expression by stimulated CD3+CD8- circulating T lymphocytes in UNPC patients and healthy donors Figure 3
Membrane CD40L expression by stimulated CD3+CD8- circulating T lymphocytes in UNPC patients and healthy donors. The 
analysis was carried out using a two-color flow cytometric assay coupled with a previously described gating strategy [42]. The 
percentage of stimulated CD3+CD8- expressing membrane CD40L is indicated on the y axis. A significantly lower percentage 
of CD3+CD8- T cells from UNPC patients up-regulated CD40L upon stimulation as compared to controls (p < 0.001). The 
difference remained statistically significant also after correction for the number of CD4+ cells.Infectious Agents and Cancer 2007, 2:5 http://www.infectagentscancer.com/content/2/1/5
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keeping with the hypothesis that sCD40L is not a product
of tumor cells, being rather part of a still poorly defined
anti-tumor immune response. On these grounds, addi-
tional studies are required to better understand the role
played by sCD40L within the frames of the complex
immune response mounted by UNPC patients against
tumour cells. Moreover, no significant prognostic role on
clinical outcome was found for serum sCD40L in our
series. It should be considered, however, that 5-year DFS
(81%) and OS rates (62%) of our patients compare favo-
rably with the results of other UNPC series [52-54]. These
data suggest that, if active treatment strategies are used,
the prognostic impact of variables such as sCD40L may be
measurable only in larger series. On these grounds, it
would be relevant to include the evaluation of serum
sCD40L among the parameters of possible prognostic
value in studies enrolling high number of UNPC patients
from both endemic and non-endemic areas.
Immunohistochemical detection (on frozen tissue sections) of CD40L+ cells within UNPC microenvironment Figure 4
Immunohistochemical detection (on frozen tissue sections) of CD40L+ cells within UNPC microenvironment. CD40L positiv-
ity is manifested as dot-like staining on isolated small lymphocytes. A. The figure shows a high content of CD40L+ lym-
phocytes, either intermingled with tumor cells or located around UNPC tumor nests, in a case (female, 37 years old) with high 
serum levels of sCD40L. B. The figure shows few CD40L+ lymphocytes in a case (male, 34 years old) with a low content of 
sCD40L. Original magnification ×250.
Table 3: Comparison of patients with undifferentiated nasopharyngeal carcinoma according to sCD40L levels and treatment-related 
factors. North-East Italy, 1994–2003.
Characteristic§ Levels of sCD40L
High Medium-Low p
Therapy No. (%) No. (%)
CT 3 (15.0) 7 (17.1)
RT 6 (30.0) 10 (24.4)
CT+RT 11 (55.0) 24 (58.5) 0.89
Response:
Complete remission 15 (83.3) 29 (80.6)
Partial/Progression 3 (16.7) 7 (19.4) 0.80
Recurrence
None 12 (80.0) 20 (69.0)
Loco-regional 0 (0.0) 7 (24.1)
Distance 3 (20.0) 2 (6.9) 0.07
§In some items, the sum does not add up to the total because of missing values.Infectious Agents and Cancer 2007, 2:5 http://www.infectagentscancer.com/content/2/1/5
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Conclusion
The results of the present study indicate that sCD40L may
contribute to CD40 activation in UNPC cells, particularly
among LMP-1-negative cases, further supporting the cru-
cial role of CD40 signalling in the pathogenesis of UNPC.
sCD40L levels may be useful to identify UNPC patients
with occult metastases at presentation.
Methods
Patients characteristics
Sixty-one patients with histologically confirmed UNPC
were enrolled between 1994–2003 (Table 1). The medical
records were reviewed and all patients were restaged
according to the 2002 edition of the UICC/TNM classifi-
cation system. All patients received various treatment
modalities, such as cisplatin-based combination chemo-
therapy (CDDP-CT) alone (10 cases), accelerated radio-
therapy (RT) alone (16 cases) or combined treatment
including neo-adjuvant CDDP-CT plus accelerated RT (25
cases) or CDDP-CT plus standard RT (10 cases). Complete
response (CR) was defined as the complete disappearance
of all cancer lesions for at least 4 weeks. Partial response
(PR) was defined as 50% reduction of the sum of the
products of the cross-sectional diameters of all known
lesions for at least 4 weeks. No response (NR) was defined
as <50% PR or progressive disease. Fifty-four (89%)
patients were assessable for treatment response. Seven
(11%) patients were not assessable because of early
deaths due to co-morbidity (4 cases) or toxicity (3 cases).
As control group, 71 healthy donors matched for sex and
age (51 males, 20 females; mean age of 47.3 ± 11.3 rang-
ing from 20 to 68 years) were also evaluated. Informed
consent was obtained from each subject.
Histopathological diagnosis and immunohistochemistry
Primary and metastatic UNPC were diagnosed according
to histologic criteria provided by W.H.O. classification for
nasopharyngeal carcinomas [7]. Cases with morphologi-
cal characteristics of non-keratinizing undifferentiated
carcinoma [7] were selected for the study. EBV infection
was detected in all cases by EBER in situ hybridization per-
formed as previously reported [55]. Immunohistochemis-
try for LMP-1 expression was carried out on paraffin-
embedded tissue sections using the CS1-4 antibody
(DakoCytomation, Glostrup, Denmark) and the APAAP
method [56]. Immunohistochemical detection of CD40L
was carried out on frozen sections obtained from 4
nasopharyngeal samples and 1 lymph node involved by
UNPC by the APAAP technique [56] and the anti-CD154/
CD40L 24–31 antibody (IgG1; Ancell Corporation, Bay-
port, MN). In each case, the percentage of CD40L+ lym-
phocytes was derived from the number of CD40L+
lymphocytes counted on a total of 100 lymphocytes eval-
uated. Negative control experiments were performed by
incubating sections with irrelevant isotype-matched
mouse Ig and by omitting the primary antibody.
Sample collection and immunoassays
Serum samples were collected from 61 UNPC patients
and 71 matched healthy donors. Plasma was also
obtained from 32 UNPC patients and 30 donors using Na
citrate 3.8% (1:9 v:v) as anticoagulant, immediately cen-
trifuged at 1,500 × g at 4°C for 20 min, aliquoted, and
stored at -80°C until analysis. Measurement of serum
sCD40L levels was carried out using a commercially avail-
able enzyme-linked immunosorbent assay (ELISA) based
on the sandwich principle, according to manufacturer's
instructions (Immunokontact; sensitivity: 0.0095 ng/ml).
Prothrombin fragment 1+2 (F1+2) levels were measured
in plasma samples by a commercially available enzyme
immunoassay (Enzygnost F1+2; Dade-Behring; reference
range: 0.4–1.1 nmol/L). Measurements were done
blinded. All samples were assayed in duplicate, and those
showing values above the standard curve were re-tested
with appropriate dilutions.
EBV DNA load quantitation
Serum EBV DNA levels were measured by amplifying a 65-
bp DNA fragment of the LMP-1 gene using a previously
described real-time PCR assay [57]. The reaction was per-
formed in a 25 μl volume containing 2× TaqMan Univer-
sal Master Mixture, 1.5 mM MgCl2, 99 pmol of each
primer (forward: 5'-AAGGTCAAAGAACAAGGCCAAG-3',
nucleotides 168,231–168,252; reverse: 5'-GCATCG-
GAGTCGGTGGG-3', nucleotides 168,188–168,204), 175
pmol of the fluorogenic probe (5'-6-FAM-AGGAGCGT-
GTCCCCGTGGAGG-TAMRA-3') and 5 μl of sample.
Standard curves were generated using the diploid
Namalwa cells, which stably harbours two integrated cop-
ies of the EBV genome. The method was linear over four
orders of magnitude and sensitive to as few as 5 copies of
template EBV DNA. To check for PCR inhibition, each
sample was also co-amplified with a positive control (500
EBV DNA copies/reaction from Namalwa cells). Results
were expressed as copies of EBV genomes/ml of serum.
Immunophenotypic analyses
A two-color flow cytometric assay was used to study
CD40L expression on resting and activated circulating T
cells. Briefly, peripheral blood mononuclear cells
(PBMCs) were isolated from citrated venous blood by
centrifugation over Ficoll-Hypaque (1500 rpm, 30 min).
Isolated PBMCs were washed three times with PBS and
incubated at room temperature for 20 min with appropri-
ate antibody combinations. Activation of T cells was car-
ried out by incubating purified PBMCs (0.4 × 106 cells/
ml) in RPMI 1640, 10% FCS in the presence of 20 ng/ml
phorbol 12-myristate 13 acetate (PMA, Sigma, Milan),
and 0.75 μg/ml ionomycin (Sigma) for 5 hr in 5% CO2 atInfectious Agents and Cancer 2007, 2:5 http://www.infectagentscancer.com/content/2/1/5
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37°C. Cell were harvested, washed and labeled with
CD40L-PE/CD3-FITC or CD40L-PE/CD8-FITC antibody
combinations. CD40L expression on T helper lym-
phocytes was evaluated using a previously described gat-
ing algorithm [42] which included both lymphocytes
(using forward scatter parameters) and CD3+CD8- T lym-
phocytes (using fluorescence parameters). This gating
strategy allowed the evaluation of CD4+ lymphocytes
(contained in the population of CD3+ CD8- T cells) and
was necessary because the CD4 molecule itself is down-
modulated after stimulation. Results are expressed as
either the percentage of CD3+CD8- T lymphocytes
expressing CD40L or the level of CD40L expressed per T
helper cell (mean fluorescence intensity). Isotype-
matched FITC- and PE-conjugated mouse IgG1 (Beck-
man-Coulter, Milan) were used as negative controls. After
incubation, each sample was washed twice with PBS, re-
suspended in PBS and immediately analyzed in an Epics
Altra flow cytometer (Beckman-Coulter). A total of
10.000 cells were acquired and analyzed by Expo 32 soft-
ware (Beckman-Coulter).
Statistical analysis
sCD40L levels were categorized in two groups based on
frequency distribution: medium-low, (≤18 ng/ml), or
high (>18 ng/ml). The association between sCD40L levels
and personal characteristics, clinical and biological
parameters was tested by means of the chi-square test (chi-
square test for trend, when appropriate) or the Student's
T-test. The overall survival (OS) was computed from the
date of UNPC diagnosis to death or to the last known date
of examination, whereas the disease-free survival (DFS)
was calculated (for CR patients only) from the date at
starting therapy to date of relapse, death or the last known
date of examination. Both the OS and the DFS were statis-
tically assessed by means of the Kaplan-Meyer method.
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